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ABSTRACT  
A new concept in multifunctional anti-cancer agents is demonstrated. Tetrakis-(diisopropyl-
guanidino) zinc phthalocyanine “Zn-DIGP” exhibits excellent properties as a photodynamic 
therapy (PDT) agent, as well as potential anti-metastatic activities in vivo. Zn-DIGP exhibits 
good cellular uptake and low toxicity in the dark (EC50 > 80 µM), and is well tolerated upon its 
intravenous injection into mice at 8 mg / kg. Upon photoexcitation with red laser light (660 nm), 
Zn-DIGP exhibits a high quantum yield for singlet oxygen formation (Φ ≈ 0.51) that results in 
potent phototoxicity to cell cultures (EC50 ≈ 0.16 µM). Zn-DIGP is also capable of inhibiting the 
formation of tumor colonies in the lungs of C57BL/6 mice injected with B16F10 cells. Zn-DIGP 
therefore inhibits cancer growth by both light-dependent and light-independent pathways. The 
anti-metastatic activities of Zn-DIGP possibly result from its ability to interfere with the 
signaling between chemokine CXCL10 and the G protein-coupled receptor CXCR3. Zn-DIGP is 
a competitive inhibitor of CXCR3 activation (IC50 = 3.8 µM), and it selectively inhibits 
downstream events such as CXCL10-activated cell migration. Consistent with the presence of 
feedback regulation between CXCR3 binding and CXCL10 expression, Zn-DIGP causes 
overexpression of CXCL10. Interestingly, Zn-DIGP binds to CXCR3 without activating the 
receptor, yet is able to cause endocytosis and degradation of this GPCR. To the best of our 
knowledge, Zn-DIGP is the first PDT agent that can facilitate the photodynamic treatment of 
primary tumors while simultaneously inhibiting the formation of metastatic tumor colonies by a 
light-independent mode of action.  
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Skin cancers account for about half of all cancers in the United States, where complications 
associated with the spread of melanoma to vital organs are a leading cause of death for women 
aged 19 to 50 years.(1, 2) While surgery remains the main treatment option for advanced 
malignancies,(3) early-stage melanoma and non-melanoma skin cancers can be treated with 
photodynamic therapy (PDT).(4-6) Photodynamic therapy involves utilization of 
photosensitizers that exhibit phototoxicity by two common mechanisms, Type 1 involves long-
lived triplet states of the photosensitizer that react directly with cellular components; Type 2 
involves formation of singlet oxygen which triggers cell death.(7) Many photosensitizing agents 
have been evaluated in the clinic,(8, 9) but only four PDT agents, all of which being porphyrin 
derivatives, are currently approved by the FDA: Verteporfin (Visudyne®), Porfimer Sodium 
(Photofrin®), 5-aminolevulinic acid (Luvulan®), and 5-aminolevulinic acid methyl ester 
(Visudyne®). None of these PDT agents, however, are ideal candidates for treating melanoma. 
In clinical trials, poor results were obtained when porphyrin-based PDT agents were used to treat 
melanoma and related maladies.(10) One key limitation to these compounds is their relatively 
short maximal wavelengths of excitation (λmax ≈ 630 nm), where melanin-rich tissues absorb too 
much light energy to be useful.(4) In terms of tissue permeability, photosensitizers with longer 
wavelengths of excitation should provide better treatment options.(11) For example, the chlorin-
based derivative e6 (λmax ≈ 660 nm) was successfully used to treat melanoma-derived skin 
metastases in human patients,(5) and a related compound “mono-L-aspartyl chlorin e6” exhibited 
good efficacy in a Phase II clinical trial.(12) Phthalocyanines (λmax ≈ 690 nm) exhibit absorbance 
into the near-infrared,(13) and can therefore utilize longer wavelengths of light than porphyrins 
and chlorins for better tissue permeability. 
 
The photophysical properties of phthalocyanines are known to be strongly influenced by the 
centrally-coordinated metal ion. For example, copper-containing phthalocyanines are essentially 
photo-inert and used as tattoo inks; while aluminum, silicon, and zinc-containing 
phthalocyanines are highly phototoxic.(14) Zinc and silicon-containing phthalocyanines have 
exhibited promising PDT activities in pre-clinical and phase-I clinical trials for chroidal 
neovascularization and cutaneous neoplasms.(15, 16) However, the notorious insolubility and 
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aggregation properties of phthalocyanines can negatively affect their cellular uptake and ability 
to act as photosensitizers.(17) Given these limitations, efforts have been directed towards the 
synthesis of water soluble and cell-permeable phthalocyanine derivatives.(18) For example, we 
recently synthesized a new family of cationic phthalocyanines termed “guanidino 
phthalocyanines” (GPcs) containing four guanidinium groups.(19) One such derivative, tetrakis-
(diisopropyl-guanidine) zinc phthalocyanine “Zn-DIGP” exhibits good cellular uptake and the 
ability to modulate gene expression.(20, 21) Presumably as a result of its high affinity binding 
interaction with a G-quadruplex from the c-myc promoter (Kd < 2 nM), Zn-DIGP can knock-
down c-myc transcription at subtoxic doses in time-dependent manner.(20) The c-myc oncogene 
encodes for a transcription factor that, together with ATF-2, plays an important role in 
proliferation, differentiation and apoptosis of melanoma.(22) Abnormal c-Myc expression can 
lead to tumorigenesis,(23) and the inhibition of c-Myc in mouse models causes melanoma 
regression.(24) Given these results, we decided to evaluate the anti-metastatic activities of GPcs 
in vivo.  
 
Here we report that Zn-DIGP inhibits the formation of metastatic tumor colonies in the lung 
tissues of mice injected with B16F10 cells. Contrary to our expectations, this inhibition appears 
to proceed via a G-quadruplex independent mode of action. According to cell-based studies, the 
anti-metastatic activities of Zn-DIGP are probably a result of its ability to disrupt signaling 
between chemokine CXCL10 and its receptor CXCR3.(25-27) Zn-DIGP binds to CXCR3 and 
inhibits CXCL10-induced receptor activation with an IC50 = 3.8 µM. Unlike previously reported 
CXCR3 antagonists, Zn-DIGP also exhibits potent phototoxicity as well as the ability to cause 
CXCR3 endocytosis and degradation. Taken together, these results suggest that Zn-DIGP and 
other GPcs may serve as multi-functional PDT agents, where light energy can be harnessed for 
the treatment of primary surface tumors while simultaneously inhibiting the formation of new 
tumor colonies by interfering with chemokine signaling. 
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RESULTS AND DISCUSSION 
GPcs: Photophysical Properties and Phototoxicity  
During our initial synthesis of guanidino phthalocyanines (GPcs), a new de-metallation reaction 
that furnished tetrakis-(diisopropyl-guanidine) phthalocyanine “DIGP” (1) as a single 
regioisomer was discovered.(19, 20) Metal ions such as Zn(II), Cu(II), Co(II), and Pd(II) can be 
inserted into 1 to give Zn-DIGP (2), Cu-DIGP (3), Co-DIGP (4), and Pd-DIGP (5), respectively 
(Figure 1). Compounds 1 – 5 exhibit excellent solubility and obey Beer’s law in DMSO over a 
concentration range of 0.3 – 5 µM (see Supporting Information, Supplementary Figures S1-S2 
for absorbance, excitation and emission spectra). We therefore measured the quantum yields for 
photon emission and singlet oxygen generation of 1 – 5 in DMSO (Table 1). The known zinc 
phthalocyanines “Zn-Pc” (6) and zinc phthalocyanine tetrasulfonate “Zn-PcS4” (7) were 
included as reference compounds. The quantum yield of Zn-DIGP for luminescence (Φ = 0.28) 
was more than 100-fold higher than the other metal-containing DIGPs (Table 1). The bright 
emissions from Zn-DIGP facilitate its direct visualization in cells using fluorescence microscopy. 
Upon its addition to living B16F10 cells, strong staining of perinuclear organelles and trafficking 
vesicles by Zn-DIGP can be observed (Figure 2 A-C). No measurable change in cellular 
respiration was observed in these samples, consistent with the minimal toxicity of Zn-DIGP 
under conditions of ambient light (Figure 3A, (-) laser). Similar to guanidinium-rich peptides that 
are known to enter cells via endocytosis,(28) Zn-DIGP co-localizes with “Lysotracker” in living 
cells (Supplementary Figure S3). Upon irradiation with 20 joules of far-red light (660 nm), Zn-
DIGP-treated cells exhibit large morphological changes and the loss of cellular respiration, 
consistent with phototoxicity (Figure 3A, (+) laser). Interestingly, a redistribution of Zn-DIGP 
from the endosomes and lysosomes of living cells to the nuclei of dying cells was observed 
following irradiation (Figure 2 D-F). This behavior is consistent with endosomal escape and 
accumulation of Zn-DIGP at high-affinity DNA binding sites upon cell death. Together these 
results suggest that Zn-DIGP is not freely diffusible across plasma membranes and it therefore 
has limited access to nuclear DNA in living cells.     
 
The cytotoxic and phototoxic activities of Zn-DIGP were quantified using a standard Alamar 
Blue assay that reports the combined effects of proliferation and metabolism on total cellular 
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respiration. B16F10 cells were treated with variable concentrations of 1 – 7 for 24 hours and 
irradiated with a 660 nm laser (250 mW) for 90 seconds. Three hours later, resazurin was added 
and its metabolic conversion into resorufin was compared with untreated cells to determine EC50 
values (see Figure 3A for representative data). A comparison of EC50 values for irradiated (+hν) 
versus non-irradiated samples (-hν) reveals the relative phototoxicity of each compound (Table 
1). The metal-free compound “DIGP” (1) shows no significant change in cytotoxicity upon 
irradiation (EC50 ≈ 30 µM), whereas the metal-containing derivatives 2 – 7 all exhibit minimal 
dark toxicity (EC50 > 80 µM) and highly variable toxicity upon irradiation (EC50 = 0.2 – 80 µM, 
Table 1). Of all derivatives tested, Zn-DIGP exhibits the most potent phototoxicity, with more 
than a 400-fold decrease in EC50 value (EC50 = 0.16 µM) upon irradiation. According to these 
results, Zn-DIGP is approximately 20-times more phototoxic than the well-studied anionic 
phthalocyanine “Zn-PcS4” (7).(29, 30)    
 
To determine the probable mechanism of Zn-DIGP’s phototoxicity, the quantum yield of singlet 
oxygen was measured for compounds 1 – 7 by monitoring the time-dependent photobleaching of 
1,3-diphenyl isobenzofuran (DPBF).(31) Consistent with the low quantum yields of singlet 
oxygen formation reported for other metal-free phthalocyanines,(32-34) DIGP exhibits very little 
photobleaching of DPBF (Figure 3B), and no changes in cytotoxicity were observed upon 
irradiating DIGP-treated cells (Table 1). Consistent with “Type 2” photosensitization in cells, the 
quantum yields for singlet oxygen formation of each M-DIGP derivative correlates with its 
relative phototoxicity, where Zn > Pd >> Cu / Co (Figure 3B, Table 1). This trend can be 
explained by the magnetic properties of each metal-containing phthalocyanine.(34) Derivatives 
containing paramagnetic ions (copper, cobalt) generate little or no detectable singlet oxygen, 
whereas derivatives containing diamagnetic metal ions (palladium and zinc) exhibit high 
quantum yields for singlet oxygen (Φ = 0.41 and 0.51, respectively). Since all three of the Zn-
containing phthalocyanines (2, 6, and 7) exhibited similar quantum yields for singlet oxygen 
formation (Φ ≈ 0.5 – 0.6), the large differences in phototoxicity between Zn-DIGP (EC50 = 0.16 
µM) and Zn-PcS4 (EC50 = 2.7 µM) are likely due to differences in their cellular uptake.(17) 
Zn-DIGP: Anti-Metastatic Activities In Vivo 
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Previous studies have demonstrated that Zn-DIGP can knock-down transcription of the c-myc 
oncogene 3-fold or more in cell cultures.(20) Given the important functions of c-myc in 
mediating melanoma metastasis,(22-24, 35, 36) we decided to evaluate the anti-metastatic 
activities of Zn-DIGP using an assay that mimics the hematogenous spread of malignant 
melanoma in vivo. (39) C57BL/6 mice were intravenously injected into the tail vein with 
B16F10 cells, and after 20 days the animals were sacrificed and the number of lung metastases 
determined by visual inspection. Control animals receiving untreated cells or cells treated with 
carrier only (sodium trifluoroacetate in DMSO) contained 38 ± 8 (average ± standard deviation) 
lung metastases on day 20. Cell cultures that were pre-treated with 5 µM of Zn-DIGP prior to 
their injection into the mice were incapable of establishing lung tumors (Figure 4, Supplementary 
Figure S4). Importantly, no changes in cellular respiration or proliferation of the cells were 
observed at this concentration of Zn-DIGP (Figure 3A, (-) light). In a second, more stringent 
experimental design (type B), untreated B16F10 cells were injected into the animals on day one, 
and a solution of Zn-DIGP was injected into the animals at 8 mg / kg on day two. All Zn-DIGP-
treated animals reacted well to the injection, showed no signs of stress, and survived the duration 
of the experiment to day 20. In this experiment, the intravenous application of Zn-DIGP caused 
an approximate 50% reduction in the number and size of lung metastases on day 20 (Figure 4, 
Supplementary Figure S4). 
 
Microarray, qRT-PCR, and ELISA for Mechanistic Lead Identification  
To provide a relatively unbiased approach for identifying the probable mechanism(s) of Zn-
DIGP’s anti-metastatic activities, its impact on global gene expression was evaluated using 
microarray analyses. Compared to B16F10 cells treated with cisplatin,(39) Zn-DIGP-treated cells 
exhibited relatively few differentially expressed genes (Supplementary Figure S5). The addition 
of Zn-DIGP caused only 40 genes to be differentially expressed with a 2-fold or larger change in 
mRNA quantities after a 24 hour treatment. Putative G-quadruplex sequences were mostly 
absent in the promoter regions of these 40 genes. qRT-PCR experiments confirmed that Zn-
DIGP caused little or no change in the transcription of c-myc and other genes containing putative 
G-quadruplex structures in their promoters such as MTA1, VEGF(40) and RB1(41) in B16F10 
cells (Supplementary Figure S6). The inability of Zn-DIGP to impact global gene expression in a 
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G-quadruplex-dependent manner is possibly related to its mechanism of cellular uptake that 
results in limited access to nuclear DNA in living cells (Figure 2 A-C, and Supplementary Figure 
S3).  
 
Repetition of the microarray analysis in an experiment where the fluorescent dyes on each primer 
were inverted, revealed only a single differentially expressed gene common to both experimental 
designs. qRT-PCR experiments confirmed that the addition of Zn-DIGP causes overexpression 
of CXCL10 in B16F10 cells in both a dose- and time- dependent manner (Figure 5). According 
to ELISA experiments, the changes in extracellular CXCL10 protein levels upon addition of Zn-
DIGP were also dose- and time-dependent (Figure 6). Zn-DIGP caused as much as a 20-fold 
increase in CXCL10 protein expression upon its addition to B16F10 cells at sub-toxic doses (5 
µM in the dark). To the best of our knowledge, Zn-DIGP is the first small molecule reported to 
induce CXCL10 overexpression.  
 
Zn-DIGP Interference of CXCR3-CXCL10 Signaling  
B16F10 cells are known to express both CXCL10 and its receptor CXCR3.(42) The high-affinity 
interaction between CXCL10 and CXCR3 (Kd ≈ 0.2 nM) is mediated by arginine, lysine and 
isoleucine residues of CXCL10 that bind to an acidic patch on CXCR3.(43, 44) The similar 
physicochemical properties of CXCL10 and Zn-DIGP, both being hydrophobic cations, indicated 
that Zn-DIGP might mimic CXCL10 to competitively bind CXCR3. To test this hypothesis, 
competitive displacement experiments were conducted using immobilized CXCR3 receptors and 
125I-labeled CXCL10. As a control, unlabelled CXCL10 was titrated and the apparent Ki (0.57 ± 
0.02 nM) was found to be similar to previous reports.(45) Using this assay, Zn-DIGP was found 
to displace 125I-labelled CXCL10 with an apparent Ki of 29 ± 1 µM (Figure 7A).  
 
To evaluate the functional impact of CXCR3 binding by Zn-DIGP, agonist assays were 
performed by monitoring changes in intracellular calcium levels in Chem 1 cells that overexpress 
CXCR3. As a control, unlabelled CXCL10 was titrated and the apparent EC50 value measured 
for receptor activation (13 ± 1 nM) was similar to previous reports.(45) As shown in Figure 7B, 
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the addition of Zn-DIGP did not cause any detectable increase in intracellular calcium levels, 
indicating the absence of CXCR3 activation. 
 
To test the ability of Zn-DIGP to inhibit activation of CXCR3 by CXCL10, Zn-DIGP was 
incubated with Chem 1 cells for 15 min followed by the addition of 13 nM CXCL10. Reduced 
calcium levels were observed in Zn-DIGP-treated samples (Figure 7C). The IC50 of Zn-DIGP for 
CXCL10-CXCR3 inhibition was 3.8 ± 0.6 µM. Surprisingly, the IC50 for CXCR3 inhibition was 
almost 8-fold lower than the Ki value for CXCL10 displacement (29 ± 1 µM). This apparent 
conundrum can be explained by cell surface dynamics and receptor turnover. Since CXCL10 
binding is known to initiate internalization of CXCR3,(46, 47) we speculated that Zn-DIGP 
binding might also cause receptor internalization, albeit without receptor activation. To test this 
possibility, B16F10 cells were treated with Zn-DIGP or CXCL10, and CXCR3 was visualized by 
immunofluorescence. In both the cases, a dramatic loss of CXCR3 staining was observed after 1 
– 2 hours of incubation (Figure 8). The localization of CXCR3 was also distinctly different in 
treated and untreated cells. In control samples, CXCR3 was distributed over the cell surface, 
whereas CXCL10- and Zn-DIGP-treated cells exhibited perinuclear CXCR3 accumulation 
consistent with receptor endocytosis (Figure 8). The differences between Zn-DIGP’s IC50 value 
for CXCR3 inhibition (3.8 µM) and CXCR3 affinity (Ki = 29 µM) can therefore be attributed to 
the ability of Zn-DIGP to bind CXCR3 without activation of the receptor, yet causing 
endocytosis and degradation of CXCR3. To the best of our knowledge, Zn-DIGP is the first 
small-molecule GPCR antagonist reported to cause receptor internalization and degradation.  
 
To assess the ability of Zn-DIGP to selectively inhibit CXCR3 downstream signaling, we 
investigated CXCL10-activated cellular motility using scratch assays (Figure 9).(25, 48, 49) As a 
selectivity control, the chemotactic cytokine CCL21 that binds to receptor CCR7 was 
included.(50) Both CXCL10 and CCL21 stimulate cell migration in the absence of Zn-DIGP 
(“untreated” samples, Figure 9B). In the presence of 5 µM, the changes in migration indices 
reveal inhibition of CXCL10-mediated cellular migration, but not of CCL21-activated migration 
(Figure 9). Similar results were also obtained using matrigel-based invasion assays 
(Supplementary Figure S7). Interestingly, the same migration index was observed for cells 
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treated with 5 µM of Zn-DIGP from 2 – 100 nM of added CXCL10 (Figure 9). Together these 
results are consistent with the ability of Zn-DIGP to selectively inhibit CXCL10-mediated 
signaling via CXCR3 binding and endocytosis.  
 
CONCLUSIONS 
Metastatic melanoma is currently associated with such poor patient outcomes that clinical trial 
participation has been recommended as standard care.(51) One novel approach to the treatment 
of melanoma malignancy is the utilization of PDT agents for destroying the primary tumor while 
simultaneously inhibiting the formation of metastases throughout the body. As a proof of 
principle, we have demonstrated that Zn-DIGP exhibits excellent properties as a PDT agent, as 
well as the ability to inhibit formation of tumor colonies in the lungs of C57BL/6 mice injected 
with B16F10 cells. To the best of our knowledge, Zn-DIGP provides the first example of a 
preclinical candidate possessing both of these properties. While the PDT activities of Zn-DIGP 
still need to be assessed in vivo, previous studies have demonstrated that an octadecyl zinc 
phthalocyanine "ZnODPc" exhibits tumor-selective accumulation and high phototherapeutic 
efficacy in Balb/c mice bearing MS-2 fibrosarcoma upon intravenous injection at 2.5 mg/kg.(52)  
 
Experiments to characterize the anti-metastatic activities of Zn-DIGP and its potential mode of 
action were conducted using a concentration of 5 µM, where no changes in cellular respiration or 
proliferation were observed under conditions of ambient light. Given the extreme side effects of 
cytotoxic chemotherapies currently used for treating metastatic melanoma,(51) the ability of Zn-
DIGP to interfere with metastasis formation without indiscriminant cell killing presents a highly 
attractive possibility. The CXCR3 antagonist “AMG487” was also reported to have little or no 
impact on cellular proliferation in serum-containing media.(25, 27). Consistent with its low 
toxicity, AMG487 did not impact local tumor growth or survival in vivo, but it was able to 
inhibit metastasis.(25) In the case of Zn-DIGP, the site-specific destruction of the primary tumor 
can be achieved using laser light activation, while simultaneously inhibiting the formation of 
new metastases in vital organs by interfering with chemokine signaling.            
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Zn-DIGP is well-tolerated upon intravenous injection into C57BL/6 mice at 8 mg / kg, where it 
exhibits a light-independent mode of action by inhibiting the formation of pulmonary metastases. 
While other modes of action can not be excluded, microarray analyses, qRT-PCR, and ELISA 
experiments all indicate that Zn-DIGP causes overexpression of CXCL10. The beneficial role of 
CXCL10 in melanoma regression is well characterized, and it has been attributed to two related 
functions: 1) enhancement of immune response by natural killer cells,(53, 54) and 2) induction of 
anti-angiogenic signals.(55) Previous studies using an adenovirus expression vector 
demonstrated that B16F1 melanoma tumors overexpressing CXCL10 by 50% exhibited 
diminished proliferation and invasiveness in vivo.(55) Upon adding 5 µM of Zn-DIGP to 
B16F10 cells, we observed a 1,000% increase in CXCL10 production in vitro, and an almost 
total loss of metastatic colony formation in vivo.   
 
Interestingly, Zn-DIGP causes CXCL10 overexpression and it inhibits CXCR3 activation when 
applied to cells. Previous studies have demonstrated that RNAi knock down of CXCR3 causes a 
reduction in the metastatic activities of B16F10 cells in C57BL/6 mice.(48) Likewise, the 
CXCR3-selective antagonist “AMG487” inhibits metastasis in a breast cancer model.(25) 
According to CXCL10 displacement assays in vitro, Zn-DIGP binds to CXCR3 with a modest Ki 
of only 29 µM, but it exhibits an 8-fold more potent IC50 value for CXCR3-CXCL10 inhibition 
on living cells (IC50 = 3.8 µM). The unexpected differences between these values, where Ki > 
IC50, can be explained by the ability of Zn-DIGP to bind CXCR3 without activation of the 
receptor, yet causing endocytosis and degradation of this GPCR. While there is small handful of 
peptide antagonists known to cause internalization of GPCRs,(56, 57) Zn-DIGP represents, to 
the best of our knowledge, the first small-molecule GPCR antagonist reported to cause receptor 
internalization and degradation. Given the exceptionally broad importance of GPCRs as drug 
targets, this unusual mode of receptor inhibition might provide an attractive direction for the 
future development of GPCR antagonists. 
 
To the best of our knowledge, Zn-DIGP is the first compound reported to cause both CXCL10 
overexpression and CXCR3 inactivation in cell cultures. While the exact relationships between 
these activities is unknown, previous studies have suggested the presence of complex autocrine 
signaling and feedback regulation between CXCL10 and CXCR3.(42) It is therefore possible 
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that the Zn-DIGP-mediated inactivation and internalization of CXCR3 is responsible for the 
overexpression of CXCL10. Previous studies have further demonstrated that the overexpression 
of CXCL10 or the inhibition of CXCR3 are independently sufficient for causing anti-metastatic 
effects in vivo.(25, 55) The potential therapeutic advantage or disadvantage of a single 
compound exhibiting both activities will be the subject of future studies.  
 
 
 
METHODS 
Cell Lines and Media. Murine metastatic B16F10 melanoma cell line were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) supplemented with 2% heat-
inactivated fetal calf serum (FCS) and 100 U/ml of penicillin (Sigma), 100 µg/ml of 
Streptomycin (Sigma).  Cells were grown in 5% CO2 at 37 °C. 
Cytotoxicity and Phototoxicity Studies. B16F10 (~10’000 cells) were seeded in 96 well plates 
and grown for 24 h prior to their incubation with variable concentrations of compounds 1 – 7 for 
24 h. Individual wells were then photoexcited with a 250 mW diode laser (containing a beam 
spreader to diameter = 1 cm) at 660 nm for 90 seconds. After 3 h of incubation in the dark under 
standard conditions (Cell Lines and Media section), the cellular media were replaced with fresh 
media containing 86 µM resazurin (Sigma) and incubated at 37 ºC. Fluorescence intensities were 
measured after 2 – 4 h using M5 spectrophotometer with excitation at 560 nm, emission at 590 
nm, and a 570 nm cutoff filter. All samples were compared to untreated cells to calculate the % 
decrease in respiration, from which EC50 values were calculated. 
Microscopy. B16F10 cells (~15’000) were seeded in Labtek 8 chambered plate (Nunc) in media 
containing 10% FCS. After overnight growth, media was replaced with fresh media containing 3 
µM Zn-DIGP and incubated for 24 h. Individual wells were then photoexcited with a 250 mW 
diode laser (containing a beam spreader to diameter = 1 cm) at 660 nm for 90 seconds. Images of 
the unfixed cells were collected using Leica LX wide field microscope before irradiation, as well 
as 3 h following irradiation with a 250 mW diode laser (containing a beam spreader to diameter 
= 1 cm) at 660 nm for 90 sec. 
Animal Studies. C57BL/6 mice were bred in the animal facility of the Institute of Medical 
Virology, University of Zurich, and used at 6-8 weeks of age. All experiments were conducted 
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according to the Guide for the Care and Use of Laboratory Animals. Zn-DIGP (trifluoroacetate 
salt) was diluted into DMSO at a concentration of 10 mM (15.5 mg / mL). Alternatively, as a 
control vehicle, 40 mM solutions of sodium trifluoroacetate were prepared in DMSO. Zn-DIGP 
and control solutions were diluted 10-fold into DMEM + 10% FCS to make 1 mM and 4 mM 
solutions and sterile filtered immediately prior to their application onto cells or injection into 
mice. In the first series of experiments (type A), B16F10 cell cultures were incubated in standard 
media containing 5 µM of Zn-DIGP or 20 µM sodium trifluoroacetate and 10% FCS for 16 h. 
The cells were then trypsinized and washed twice with PBS and diluted to 2 x 105 cells in a total 
volume of 200 µl. The formation of pulmonary metastases was established by intravenous 
injection of Zn-DIGP-treated or control cells into the tail vein of C57BL/6 mice. Twenty days 
later, the animals were sacrificed and numbers of lung metastases were examined by visual 
inspection of lungs.(37, 38) In a second series of experiments (type B), 2 x 105 cells of B16F10 
cells, in 200 µl of PBS were injected into the tail vein of C57BL/6 mice. On the second day, the 
mice were injected with 100 µL of 1 or 4 mM solutions of Zn-DIGP or sodium trifluoroacetate 
carrier (prepared in DMEM + 10% FCS as described above). Twenty days later the animals were 
sacrificed and numbers of metastases were examined by visual inspection of lungs. The results 
for untreated animals were the same as those receiving the carrier only. The results are shown as 
numbers of metastases in individual mice. Bars represent relative numbers of metastases +/- 
standard errors from two independent experiments. 
[125I] CXCL10 Displacement Assays. Zn-DIGP was dissolved in DMSO at a concentration of 
100 mM and serial dilutions were conducted in DMSO. 60-fold dilutions were then made into an 
equilibrium binding buffer (water supplemented with 50 mM HEPES, 5 mM MgCl2, 1 mM 
CaCl2, 0.2% BSA at pH 7.4) to concentrations that were four-fold higher than the final assay 
concentration. CXCL10 and Zn-DIGP were mixed 1:1 (v/v) with [125I]-CXCL10 to a final 
concentration of 0.1 nM and added to CXCR3 membranes (Millipore) prepared in assay buffer at 
1 unit/well. The assay plate was incubated at rt for 120 min. Prior to CXCL10 capture, the FC 
filter plate (Millipore) was pre-coated with 0.3% Polyethyleneimine (PEI) for one hour. 
Following capture, the FC filter plate was washed three times (50 mM HEPES, pH 7.4, 500 mM 
NaCl, and 0.1% BSA). The filtration plate was allowed to dry and 50 µL per well of scintillation 
fluid was added and counted on a Perkin Elmer (Wallac) 1450 Microbeta TriLux liquid 
scintillation counter. Ki values were calculated based on the Cheng-Prusoff equation; Ki = IC50/[1 
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+ ([L]/Kd), where IC50 is the half maximal inhibition concentration, [L] is the CXCL10 ligand 
concentration (0.1 nM), Kd is the measured equilibrium dissociation constant (0.2 nM) of the 
CXCL10 - CXCR3 binding interaction.  
Ca2+ Flux Assays. Chem1 cells (~ 50,000) that overexpress CXCR3 were seeded in 96 well 
plates and incubated at rt for 30 min before transferring to 37 ºC incubator for overnight 
incubation. Assay buffer (Hanks Balanced Salt Solution containing 20 mM HEPES and 2.5 mM 
Probenecid; pH = 7.4) and loading buffer (assay buffer + 5 mM Fluo-8 dye) were prepared 
freshly. The cells were then washed once with assay buffer and incubated with loading buffer for 
1.5 h. Meanwhile, Zn-DIGP was dissolved in DMSO at a concentration of 100 mM and serial 
dilutions were conducted in DMSO. 1000-fold dilutions were made into assay buffer to 
concentrations three-fold higher than the final assay concentrations. Vehicle only and positive 
controls were prepared in the same way. The CXCR3 agonist assays were conducted using a 
FLIPRTETRA instrument where Zn-DIGP, vehicle controls, and reference agonist (CXCL10) were 
added to assay plates containing the washed Chem1 cells in loading buffer, and Fluo-8 
fluorescence was read as a function of time. Upon completion of the agonist assay, the assay 
plate was removed from the FLIPRTETRA instrument and incubated at 25 °C for 7 min. After the 
incubation period, the assay plate was placed back into the FLIPRTETRA instrument and the 
antagonist assay was initiated. The antagonist assay was conducted using the same methodology 
as the agonist assays. Using the EC50 concentration of CXCL10 determined by the agonist assay 
(13 nM), all pre-incubated Zn-DIGP wells were challenged with CXCL10 after establishment of 
a fluorescence baseline. Maximum fluorescence values were used to calculate percentage 
activation, percentage inhibition (relative to EC50 and vehicle control values), and additional 
statistical values (Z`, percentage variation between replicate data values) to assess the quality of 
each plate. All dose response curves were fit using GraphPad Prism.  
Receptor Internalization Assays. B16F10 cells (~70`000) were seeded in 24 well plates 
containing cover slips in 10% FCS containing media. After 4 h, 10% FCS containing media was 
replaced with 0% FCS containing media. After overnight incubation, the used media was 
replaced with fresh 0% FCS containing media and left for 30 min. 0% FCS media containing 20 
nM of CXCL10 or 5 µM Zn-DIGP were then added and incubated for 0, 1, or 2 h. Cells were 
then washed twice with 1 ml of PBS, fixed with 3% PFA for 15 min and washed twice with PBS. 
Cover slips were stained with CXCR3 primary antibody (Abcam, 1:400 dilution in PBS 
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containing 0.1% BSA) and incubated at rt for 1 h and washed twice with PBS. Fluroscein-
labeled secondary antibody staining was performed with 1:500 dilution of the antibody (Abcam) 
in PBS containing 0.1% BSA and incubated for 1 h at rt. To visualize the nucleus, a 1:1000 
dilution of 10 mg/ml Hoechst 33258 in PBS was applied for 15 min at rt. Cells were then washed 
with PBS 5 times and imaged with a SP2 confocal microscope. 
Migration assays. B16F10 cells (~75’000) were seeded in 24 well plates for 4 h. The media was 
replaced with starvation medium (0% FCS) in the presence or absence of 5µM Zn-DIGP and 
incubated overnight. Used media was then replaced by PBS and a scratch was made with sterile 
pipette tip and the detached cells were removed. Starvation media containing variable 
concentrations of CXCL10 or CXCL10 + 5 µM of Zn-DIGP was added to the cells. Bright field 
images with 4x objective were taken immediately after the scratch and after 24 h of incubation. 
The area of scratch was calculated using Image J software. The migration index is defined as the 
ratio of the area of scratch made at time 0 h to the area of scratch at 24 h. 
Associated Content 
Supporting Information Available: Synthesis and characterization of compounds 3 – 5, as well as 
detailed protocols for microarray analyses, qRT-PCR and ELISA are included in supporting 
information. This material is available free of charge via the Internet at http://pubs.acs.org. 
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Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table legend 
 
Table 1 Quantum yields (Φ) for singlet oxygen and luminescence of phthalocyanines 1 – 7. EC50 
values for B16F10 cells were determined in the absence of light (-hv) or following a 90 second 
exposure to red laser light (+hv) at 660 nm. EC50 values for compound 6 were not determined 
“ND” due to its poor solubility properties in aqueous media. 
 
Figure legends 
 
Figure 1 Structures of tetrakis-diisopropyl-guanidine-phthalocyanine (DIGP) derivatives 
containing various metal ions “M”, and the reference compounds zinc phthalocyanine (ZnPc) 
and zinc phthalocyanine tetrasulfonate (Zn-PcS4). 
 
Figure 2 Cellular uptake of Zn-DIGP into living B16F10 cells before (A – C) and after (D – F) a 
90 second exposure to red laser light at 660 nm. (A, D) Brightfield images. (B, E) Fluorescence 
EC50 for toxicity (µM) 
No Compound 
Φ for 
emission 
Φ for 
1O2 (-) laser (+) laser  
1 DIGP 0.26 0.06 ± .008 25 ± 5 32 ± 6 
2 Zn-DIGP 0.28 0.51 ± .05 >80 0.16 ± .08 
3 Cu-DIGP < 0.001 0.03 ± 0.006 >80 > 80 
4 Co-DIGP < 0.001 < 0.01 >80 >80 
5 Pd-DIGP 0.002 0.41 ± .02 >80 2.1 ± .14 
6 Zn-Pc 0.34 0.61 ND ND 
7 Zn-PcS4 0.29 0.50 ± .04 >80 2.7 ± 0.5 
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emission from Zn-DIGP (Ex = 620 nm, Em = 700 nm). (C) Composite image of (A – B). (F) 
Composite image of (D – E). Scale bars represent 30 µm. 
 
Figure 3 (A) Cellular respiration of B16F10 cells treated with Zn-DIGP and kept in the dark (-
laser) as compared to Zn-DIGP-treated cells irradiated with 20 joules of 660 nm laser light (+ 
laser) (B) Photobleaching of DPBF absorbance in the presence of 1 – 7 upon irradiation at 660 
nm. 
 
Figure 4 In vivo effects of Zn-DIGP on melanoma colony formation in lung tissues of C57BL/6 
mice. “Type A” experiments indicate intravenous injection of B16F10 cells pre-treated with Zn-
DIGP. “Type B” experiments indicate direct intravenous injection of Zn-DIGP 24 hours after 
injection of B16F10 cells. Vertical bars represent the mean number and standard error of tumor 
colonies present in lungs on day 20. *** and ** represent p < 0.001 and p < 0.01, respectively. 
 
Figure 5 Relative CXCL10 mRNA abundance in B16F10 cells with respect to untreated cells 
according to qRT-PCR. (A) CXCL10 mRNA versus Zn-DIGP concentrations after 24 hours. (B) 
Time-dependent changes in the presence of 5 µM of Zn-DIGP. All qRT-PCR values were 
normalized to two different housekeeping genes (β-actin and SDHA). Error bars indicate 
standard errors. 
 
Figure 6 Changes in extracellular CXCL10 protein concentrations according to ELISA. (A) 
CXCL10 versus Zn-DIGP concentrations after 24 hours. (B) Time-dependent changes in the 
presence of 5 µM of Zn-DIGP. Error bars indicate standard errors. 
 
Figure 7 (A) 125I-CXCL10 displacement following a 2 hour incubation with unlabeled CXCL10 
or Zn-DIGP. (B) CXCR3 receptor activation by CXCL10 and Zn-DIGP in Chem 1 cells 
according to intra-cellular calcium levels. (C) Inhibition of CXCL10-mediated CXCR3 receptor 
activation by Zn-DIGP in Chem1 cells according to intra-cellular calcium levels. 
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Figure 8 Confocal microscopy images of B16F10 cells stained for CXCR3 after addition of Zn-
DIGP (5 µM) or CXCL10 (20 nM). Green staining represents the CXCR3 specific antibody and 
blue staining represent nucleus specific Hoechst 33258. (A) – (C) are images taken at t = 0 of 
incubation, (D) – (F) are images taken after 1 hour following the addition of CXCL10 and Zn-
DIGP. (G) – (I) are images taken after 2 hours. In all cases, cells were fixed prior to imaging, 
and the same detector gain and laser intensities were used on the microscope. Scale bars 
represent 30 µM. 
 
Figure 9 (A) Bright field images of scratches made in monolayers of B16F10 cells. A) & B) are 
images taken immediately after addition of Zn-DIGP and/or CXCL10. C) & D) are images taken 
after 24h. Scale bars represent 50 mm. (B) Summary of scratch assay results where migration 
index is defined as the ratio of the area of scratch at 0 h versus 24 h. “Untreated” indicates 
addition of CXCL10 or CCL21 only. A migration index of 1.0 corresponds to the cellular 
migration in the absence of added chemokine.   
 
Figure 1 
N
N
N
N
N
N N
N
HNNH
NH HN
NH
N
H
HN
N
H
HN
NH
+ +
NH
HN
+ +
M
N
N
N
N
N
N N
N
Zn
 Zn-DIGP (2)
N
N
N
N
N
N N
N
SS
S S
Zn
O
O
OO O
O
O
O OO
O
O
_
_
_
_
Zn-Pc (6)
 Cu-DIGP (3)
 Co-DIGP (4)
Pd-DIGP (5)
M Compound
Zn(II)
Cu(II)
Co(II)
Pd(II)
Zn-PcS4 (7)
N
N
N
N
N
NH N
HN
HNNH
NH HN
NH
N
H
HN
N
H
HN
NH
+ +
NH
HN
+ +
DIGP (1)
M(II)
Cs2CO3
90 oC
 
23 
 
Figure 2 
 
 
Figure 3 
0.0 2.5 5.0 7.5 10.0
0
50
100
(+) laser
(-) laser
A)
Zn-DIGP Concentration (µM)
Vi
ab
ili
ty
(%
 r
es
pi
ra
tio
n)
 
 
0 5 10 15 20
0
1
2
3
4
DIGP
Zn-DIGP
Cu-DIGP
Co-DIGP
Pd-DIGP
Zn-Pc
Zn-PcS4
B)
Time (seconds)
- l
n 
(A
41
7/A
41
7(
t=
0)
)
24 
 
Figure 4 
 
 
 
 
 
 
 
 
Figure 5 
0.0 0.5 5.0 25 
1
2
3
A)
Zn-DIGP Concentration (µM)
R
el
at
iv
e 
ab
un
da
nc
e
of
 C
XC
L1
0 
m
R
N
A
0 8 18 24
1
2
3
B)
Incubation Time (hours)
R
el
at
iv
e 
ab
un
da
nc
e
of
 C
XC
L1
0 
m
R
N
A
 
 
Figure 6 
0 0.04 0.2 1 5 25
0
25
50
75
A)
Zn-DIGP Concentration (µM)
C
XC
L1
0 
(p
M
)
0 8 16 24 36 48
0
100
200
B)
Incubation time (hours)
C
XC
L1
0 
(p
M
)
 
0
20
40
60
Control Type A Type B
Zn-DIGP
***
**
Nu
m
be
r o
f t
um
or
co
lo
ni
es
 in
 lu
ng
s
25 
 
Figure 7 
-11 -10 -9 -8 -7 -6 -5 -4 -3
0
50
100
CXCL10
Zn-DIGP
A)
Log10 Concentration [M]
[1
25
I]-
C
XC
L1
0
 b
ou
nd
 (%
 o
f m
ax
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-8 -7 -6 -5 -4 -3
0
100
200
C)
Log10 Concentration [M]
N
or
m
al
iz
ed
 re
ce
pt
or
ac
tiv
at
io
n 
(%
)
-11 -10 -9 -8 -7 -6 -5 -4 -3
0
50
100
B)
Log10 Concentration [M]
N
or
m
al
iz
ed
 r
ec
ep
to
r
ac
tiv
at
io
n 
(%
)
26 
 
Figure 8 
         Untreated                CXCL10               Zn-DIGP 
 
A) B) C) 
F) 
I) 
0 
h 
   
   
   
   
   
   
   
   
   
1 
h 
   
   
   
   
   
   
   
   
 2
 h
27 
 
Figure 9 
               
         Untreated                  Zn-DIGP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graphical abstract 
 
 
 
 
A) 
0nM 2nM 20nM 50nM 100nM 20nM 
0
1
2
3
4
5 Untreated
5µM Zn-DIGP
CXCL10 CCL21
B)
M
ig
ra
tio
n 
in
de
x
0 
h 
   
   
   
   
   
   
   
24
 h
